Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01535573 · ClinicalTrials.gov registry record · Phase 2
Citalopram for Cocaine Dependence
A Phase 2 study of Cocaine Dependence, sponsored by Joy Schmitz.
- Completed
- Registry status
- Phase 2
- Development phase
- 108
- Enrollment target
- 1
- Study location
NCT01535573 is a Phase 2 study of Cocaine Dependence that has completed, run by Joy Schmitz. The registered enrollment target is 108 participants, below the 296-participant average among 38 other Cocaine Dependence trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01535573, a Phase 2 study of Cocaine Dependence, has completed, sponsored by Joy Schmitz.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 108 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase 2 clinical trial of citalopram pharmacotherapy for treatment of cocaine dependence. Using a double-blind, randomized controlled design, eligible cocaine dependent patients will be assigned equally to one of three medication conditions: placebo or the Selective serotonin re-uptake inhibitor (SSRI) agent, citalopram at either 20 mg per day or 40 mg per day. It is hypothesized that citalopram will reduce cocaine use and increase periods of sustained abstinence substantially more than placebo. Performance on a set of behavioral tasks of impulsivity will be analyzed as potential predictors of treatment response.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Citalopram
Study Locations (1)
Texas
- UT-Houston Behavioral and Biomedical Sciences Building - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2010-12 |
| Est. Completion | 2016-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01535573
The ClinicalTrials.gov registry entry for NCT01535573 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 296-participant average among 38 other Cocaine Dependence trials with a reported enrollment target (64% lower). The listed sponsor is Joy Schmitz, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cocaine Dependence appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01535573 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01535573 about?
NCT01535573 is a clinical study titled "Citalopram for Cocaine Dependence". This is a phase 2 clinical trial of citalopram pharmacotherapy for treatment of cocaine dependence. Using a double-blind, randomized controlled design, eligible cocaine dependent patients will be assigned equally to one of three medication conditions: placebo or the Selective serotonin re-uptake inh...
What is the current status of trial NCT01535573?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 108 participants. The study started on 2010-12. Estimated completion is 2016-07.
What conditions does trial NCT01535573 study?
This clinical trial studies the following conditions: Cocaine Dependence.
What interventions are being tested in trial NCT01535573?
The interventions under investigation include: Placebo (DRUG), Citalopram (DRUG).
Who is sponsoring clinical trial NCT01535573?
This trial is sponsored by Joy Schmitz, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01535573 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cocaine Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Clavulanic Acid for the Treatment of Cocaine Use Disorder
ACTIVE NOT RECRUITING · Phase 2
-
Glutamatergic Modulation of Cocaine-related Deficits
COMPLETED · Phase 2
-
Disulfiram for Cocaine Abuse
COMPLETED · Phase 2
-
Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence
COMPLETED · Phase 2
-
PHASE IIA: Trial of a Novel Ondansetron Formulation (OND-PR002) and Immediate-Release Methylphenidate (Ritalin®)(OND003IND)
COMPLETED · Phase 2
-
Clinical Trial of Topiramate for Cocaine Addiction
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.